中国医药
(600056)
| 流通市值：130.39亿 | | | 总市值：130.44亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 24,989,322,089.12 | 16,951,924,948.17 | 8,188,780,055.69 | 35,361,621,734.95 |
| 营业总成本 | 24,280,070,496.25 | 16,372,550,315.06 | 7,879,789,178.24 | 34,112,387,650.65 |
| 其他经营收益 | | | | |
| 营业利润 | 616,229,713.7 | 477,896,057.56 | 312,740,001.63 | 1,022,988,204.38 |
| 利润总额 | 615,199,997.96 | 480,338,220.38 | 314,307,790.51 | 999,294,796.62 |
| 净利润 | 390,979,786.14 | 312,220,347.57 | 237,139,518.53 | 674,635,843.84 |
| 每股收益 | | | | |
| 其他综合收益 | 21,226.5 | 573,922.49 | -1,525,891.19 | -8,387,833.07 |
| 综合收益总额 | 391,001,012.64 | 312,794,270.06 | 235,613,627.34 | 666,248,010.77 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 29,369,078,035.19 | 29,591,414,444.12 | 28,279,869,560.68 | 28,079,061,522.76 |
| 非流动资产: | | | | |
| 非流动资产合计 | 9,339,455,743.9 | 9,353,218,759.3 | 9,197,387,971.61 | 8,791,908,285.01 |
| 资产总计 | 38,708,533,779.09 | 38,944,633,203.42 | 37,477,257,532.29 | 36,870,969,807.77 |
| 流动负债: | | | | |
| 流动负债合计 | 20,531,207,475.81 | 20,446,966,002.17 | 19,873,929,214.34 | 19,725,513,963.7 |
| 非流动负债: | | | | |
| 非流动负债合计 | 3,610,736,352.49 | 3,966,467,744.46 | 3,002,547,891.92 | 2,781,857,172.81 |
| 负债合计 | 24,141,943,828.3 | 24,413,433,746.63 | 22,876,477,106.26 | 22,507,371,136.51 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 12,022,194,351.49 | 11,973,367,900.45 | 12,018,004,410.41 | 11,835,948,719.71 |
| 股东权益合计 | 14,566,589,950.79 | 14,531,199,456.79 | 14,600,780,426.03 | 14,363,598,671.26 |
| 负债和股东权益合计 | 38,708,533,779.09 | 38,944,633,203.42 | 37,477,257,532.29 | 36,870,969,807.77 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 25,758,768,318.7 | 16,860,228,897.43 | 7,369,571,599.36 | 37,405,266,841.25 |
| 经营活动现金流出小计 | 26,360,642,352.08 | 17,722,981,785.01 | 8,790,891,698.65 | 35,979,387,562.23 |
| 经营活动产生的现金流量净额 | -601,874,033.38 | -862,752,887.58 | -1,421,320,099.29 | 1,425,879,279.02 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 128,097,178.34 | 18,638,297 | 15,386,966 | 40,349,363.18 |
| 投资活动现金流出小计 | 511,566,614.04 | 443,587,341.14 | 410,952,589.83 | 339,956,644.42 |
| 投资活动产生的现金流量净额 | -383,469,435.7 | -424,949,044.14 | -395,565,623.83 | -299,607,281.24 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 5,853,984,461.29 | 3,443,500,840.04 | 1,255,193,949.95 | 6,504,330,076.46 |
| 筹资活动现金流出小计 | 5,766,916,407.03 | 2,670,221,140.85 | 1,174,008,392.73 | 8,108,643,218.95 |
| 筹资活动产生的现金流量净额 | 87,068,054.26 | 773,279,699.19 | 81,185,557.22 | -1,604,313,142.49 |
| 汇率变动对现金及现金等价物的影响 | -2,350,797.57 | -2,259,883.42 | -110,384.4 | -12,441,591 |
| 现金及现金等价物净增加额 | -900,626,212.39 | -516,682,115.95 | -1,735,810,550.3 | -490,482,735.71 |
| 期末现金及现金等价物余额 | 2,449,259,495.28 | 2,833,203,591.72 | 1,614,075,157.37 | 3,349,885,707.67 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -516,682,115.95 | - | -490,482,735.71 |